




Searching News Database: Famotidine
HSMN NewsFeed - 30 Mar 2015
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
HSMN NewsFeed - 22 Aug 2013
Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
HSMN NewsFeed - 29 Jun 2009
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 9 Jan 2009
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
HSMN NewsFeed - 3 Nov 2008
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
HSMN NewsFeed - 31 Dec 2007
Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
HSMN NewsFeed - 8 Jan 2007
Horizon Therapeutics Announces Special Protocol Assessment With FDA for Phase 3 Trial Program
Horizon Therapeutics Announces Special Protocol Assessment With FDA for Phase 3 Trial Program
Additional items found! 5

Members Archive contains
5 additional stories matching:
Famotidine
(Password required)
Famotidine
(Password required)